logo
Eureka! Increasing the Odds of a Sudden Insight

Eureka! Increasing the Odds of a Sudden Insight

Medscape4 days ago

This transcript has been edited for clarity.
Welcome to Impact Factor , your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson from the Yale School of Medicine.
At a time when the capabilities of artificial intelligences seem to be growing by leaps and bounds at an incredible pace, it's comforting to remember that there are certain cognitive processes that continue to feel distinctly human. I want to talk about one of those processes today. It's the idea of 'eureka': a sudden flash of insight, where the solution to a puzzle or a problem or a mystery just sort of clicks.
When we think about these moments, several features come to mind. First is the suddenness. It's not that you slowly improve at solving a problem, you slowly improve and slowly improve and then — all of a sudden — you dramatically improve. Then there's the timing of the insight; it's variable. Given the same puzzle, some people 'get it' quickly, and some take longer. And, of course, some people never get it at all.
This process seems so singular, so qualitative, that it may appear to be impossible to study. But a study of sudden insight is exactly what we're going to be exploring today. Let's see if it clicks.
Abandoning stories of Greek philosophers and kings' crowns, researchers, led by Anika Löwe, refer to these sudden flashes of insight as 'aha moments.'
To me, an 'aha moment' is sitting in my girlfriend's basement watching the 'Take on Me' music video, but there's never a forever thing.
Here, we're talking about those sudden flashes of insight, and, in particular, whether a bit of sleep improves the chances of having them. The paper appears in PLOS Biology.
How do you test aha moments in the laboratory? The system is really clever. Participants (90 in this study) were exposed to a very simple computer game during which dots move around a circle in different directions, but one of four directions (northwest, northeast, southwest, and southeast) is more common than the others. The participants are asked to press one of two buttons when they see the set of moving dots and are then given feedback on whether they are right or wrong. There is a hidden rule here — for example, to be correct they need to hit the left button when the majority of dots are moving northwest or southeast, but the right button when the dots are moving northeast or southwest. They have to figure this out through trial and error.
It's not that easy, especially since there is a lot of noise in the direction of travel of the dots. But, as you might expect, task performance improves over time — people figure out the rule underlying the correct answers and do better and better over hundreds of iterated trials.
As looking at the moving dots, you notice that they change color as well, from orange to purple at random. For the first 80% of trials or so, these color changes are random; they have nothing to do with the correct answer. But here's the trick: Toward the end of the series of trials, the colors start to match up with the correct directions. In other words, all of a sudden, orange dots would indicate that the participant should press the left button, purple dots the right button. But the participants have to realize this is happening; no one tells them in advance.
That requires a sudden flash of insight — an 'aha' moment. But once a participant has that moment, their performance skyrockets. It's way easier to match a color to a button than two of four noisy directional trends to a button.
I find this super clever. Major props to whatever neuroscientist had the flash of insight to design this system.
Now we have a framework for measuring aha moments. The next step is to perturb the system.
The researchers wanted to determine whether sleep (and which stage of sleep) would improve the aha phenomenon.
After an initial round of testing, where the 'color rule' appeared only at the very end, the participants went into a quiet room to nap.
An EEG was used to determine whether they merely rested or they had reached stage 1 or stage 2 of sleep. Stage 1 sleep is pretty light — almost conscious. Stage 2 is slightly deeper but not to the level of deep sleep. Only one participant reached stage 3 during the short nap.
Some people figured out the secret rule before naptime; they were excluded from further study. So now we have a group of people who had not yet had an aha moment. Would the achieved sleep stage matter when they were tested again?
It did. Pretty profoundly, too.
About 50% of the group who did not sleep at all during the rest had the color insight during the second round of testing. About 60% of those who hit stage 1 sleep had the aha moment, but 80% of people who reached stage 2 sleep had that insight — a statistically significant improvement.
Interestingly, sleep only seemed to affect the proportion of people who had the insight. It didn't affect the time to the insight. And napping had no effect on task performance prior to the insight. Rather, it seemed that napping just allowed the magic to happen.
But how does the magic happen? The researchers interrogated the EEGs to see whether something deeper was going on besides stage 2 sleep. They found that aperiodic activity in the brain captured all the information that sleep stage did. In fact, it correlated more strongly with insight than sleep stage itself. So…what is aperiodic activity, and what is happening when aperiodic activity in your brain is higher?
Aperiodic activity is electrical signals in the brain that don't have a nice repeating pattern. They seem more random and have been described as the 'background noise' of the brain. But what is interesting is what is happening to neural connections as aperiodic activity is increasing. They get weaker.
This sounds bad, but weakening connections between neurons is actually a critical thing. It allows connections that are already weak and of poor quality to break entirely, allowing the stronger connections more exclusivity. Those of you in the machine learning space will recognize the similarity to regularization methods. But basically what is happening is that the 'noise' of the complex brain is being turned down, so the signal can come through that much louder.
And maybe that is what allows the insight to happen. Perhaps a brain with a bit less noise and a bit less clutter can more clearly see the underlying structure being presented to it and make those cognitive leaps that (for now) separate humans from the neural networks we create in silico.
Of course, looking at this study I'm sure you're thinking the same thing I am: How can I leverage this knowledge to increase my likelihood of having eureka moments? Well, better sleep seems like the obvious answer here, but I think we all knew that already.
Maybe we can take a lesson from this idea of signal and noise. If the key to aha moments is allowing the stronger connections in our brain to function more cleanly, without the distraction of those weaker connections, maybe that means we need to avoid those weaker connections if possible — those distractions. Does scrolling TikTok reduce your chance of having sudden insights? Does meditating in a quiet room increase them? I'm not sure, but at least now we have a mechanism to study those questions.
In closing, let me express my wish that you have many aha moments, and that they won't be gone in a day or two.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Denis Villeneuve Is the Next Bond Director. So What Will His 007 Look Like?
Denis Villeneuve Is the Next Bond Director. So What Will His 007 Look Like?

Yahoo

time25 minutes ago

  • Yahoo

Denis Villeneuve Is the Next Bond Director. So What Will His 007 Look Like?

Arrival. Blade Runner 2049. Dune. And now, Bond. Amazon MGM Studios just named Québécois auteur Denis Villeneuve the next James Bond movie. (Colloquially known as "Bond 26" until a real title comes along.) Now wielding the keys to the Aston Martin, Villeneuve's involvement raises big questions about the future for the spy franchise. Mainly: What's Bond 26 going to look like? First, the basics. Not only will this mark Villeneuve's first time working on the series in any form, but also producers Amy Pascal and David Heyman—who took the reins from the Broccolis after they ceded control to Amazon last February. It will also be the series debut of whatever actor will play James Bond next, following Daniel Craig's retirement in 2021's No Time to Die. Truly, we're in a brave new world for Bond. "I'm a die-hard Bond fan. To me, he's sacred territory," Villeneuve said in a statement, where he added that he shared the 007 movies with his father since Dr. No with Sean Connery. "I intend to honor the tradition and open the path for many new missions to come. This is a massive responsibility, but also, incredibly exciting for me and a huge honor." Villeneuve is excited to take on Bond—who wouldn't be?!—but an auteur taking over a revered film series comes with plenty of questions and speculation that a lesser-known director wouldn't necessarily attract. Amazon MGM's choice is even more interesting when you factor Villeneuve's existing body of work, a number of which are expansive science fiction features that oscillate between refined and oppressive sensibilities. Judging by what we've broadly seen across his eleven films (beginning with his filmmaking debut August 32nd on Earth, from 1998), we might get a more tech-sophisticated Bond. You know the scenes where Bond meets Q and gets a fancy gadget? It's screaming Denis Villeneuve. And whatever the plot might be, you can bet the villain will dwell in some elaborate lair—with lots of empty space, of course—in which they pontificate their plans with deep solemnity. If Villeneuve leans toward a version of the Bond he grew up on, though, perhaps Bond 26 will be the opposite of what Blade Runner 2049 and the Dunes looked like. (Especially if Dune: Messiah, which begins filming this summer and comes out 2026, doesn't tucker him out from architectural straight lines and gunmetal-gray color palettes.) A Bond 26 that leans into funkier retro aesthetics, found in the Connery, Lazenby, and Moore eras—or the over-the-top bombast that defined Dalton and Brosnan—or something that's all of the above, seems plausible for Villeneuve. Back in 2015, Villeneuve told ComingSoon that directing Bond would be a dream, and that it would be an invitation to try something different. "I understand that each genre has its own specific rules, but for me, they are all movies," he said. "I'm just attracted to try to do different things, and I was very excited to make a movie that required more action. I was raised with James Bond. I love James Bond movies. I would love to do a James Bond movie one day. Action is very cinematic. I'm not someone that loves dialogue—I am someone that loves movement. Action, if it's well done, can be very poetic and meaningful." In a 2021 appearance on the podcast Happy Sad Confused, Villeneuve called Bond "a dream to do" and "pure cinematic joy." Whether Villeneuve's definition of joy means remaking Moonraker or making Bond even more of an iconoclast in a rapidly evolving world is yet to be seen. But the Villeneuve era of Bond is already shaping up to be the biggest paradigm shift since Craig stood up on a sandbar in Casino Royale. Basically: Get ready for Bond to get shaken, not stirred. You Might Also Like Kid Cudi Is All Right 16 Best Shoe Organizers For Storing and Displaying Your Kicks

Real-World Cases of Skin Cancer Management in Older Adults
Real-World Cases of Skin Cancer Management in Older Adults

Medscape

timean hour ago

  • Medscape

Real-World Cases of Skin Cancer Management in Older Adults

Supporting Data and the Patient's Response to Imiquimod Supporting that decision-making process was a randomized controlled trial published in 2017 comparing surgery with imiquimod 5% cream for nodular and superficial BCC, showing that imiquimod was inferior to surgery but still provided sustained benefit, Patel said. The 5-year success rates (absence of recurrence) in that trial were 82.5% compared with 97.7% for surgery (relative risk of imiquimod success, 0.84; 95% CI, 0.77-0.91; P < .001) — rates that were comparable to previously reported 3-year success rates of 83.6% and 98.4% for imiquimod and surgery, respectively. Most recurrences occurred within the first year. The 'caveat,' Patel said, was that the trial looked only at low-risk locations such as the cheek and the trunk, and not the tip of the nose. Patients with superficial BCC received 6 weeks of imiquimod cream once daily, and those with nodular BCC received 12 weeks. Use of this therapy 'requires clear explanation to the patient and an understanding of the off-label and not-fully-evaluated potential application,' Patel said in an interview after the meeting. After 6 weeks of treatment, the patient had notable crusting of the nasal tip with surrounding erythema. At 12 weeks, the tip of her nose was 'smooth with no obvious residual carcinoma notable,' Patal said at the meeting. 'She tolerated the treatment well and had a great response.' There have been suggestions made among some Mohs surgeons that the Mohs surgery AUC for primary superficial BCCs should be reevaluated, Patel said, referring to a Viewpoint piece published in JAMA Dermatology in July 2018 that pointed out that they are indolent, penetrate minimally, and are often multifocal, making them amenable to nonsurgical treatments. The lower-risk nodular BCC subtype is also worthy of AUC reevaluation, he said. Decision-Making About a Second Lesion: Melanoma In Situ (MIS) During the follow-up period, the patient's daughter noticed a large 2 cm pigmented area on her mother's wrist, and a biopsy revealed MIS. NCCN guidelines for MIS recommend surgical excision with margins of 0.5-1 cm but contain a footnote that consideration of topical immunotherapy or radiation therapy is an option in select patients with MIS of the lentigo maligna (LM) subtype, Patel said. He pointed to a retrospective review published 10 years ago looking at 63 MIS/LM cases in which imiquimod 5% cream was used as either primary or adjuvant therapy. When used as primary therapy, with no surgery, 72.7% demonstrated clinical clearance at a mean follow-up of 39.7 (range, 8-95) months. And when used as adjuvant therapy, 94.4% demonstrated clearance at a mean follow-up of 43.1 (range, 4-106) months. One could opt for primary therapy, knowing that 3 out of 4 patients might have clearance lasting over the course of several-plus years. Or, in the case of adjuvant therapy, 'you could do a partial resection or narrow margin resection, and if you have positive margins, go back and have an even higher success rate with adjuvant imiquimod cream,' Patel said. For his 88-year-old patient, 'surgery for a 2 cm tumor on the wrist, with skin that's fragile, is not easy to accomplish, certainly not easy to close up,' he said. The question was, 'could we cause more harm than good?' The patient decided on every-other-day treatment with 5% imiquimod cream for 6 weeks and responded with some clearing. She continued for another 6 weeks but on follow-up was noted to have some areas of progression. 'She ultimately needed an excision as the lesion was progressing in one area, and rebiopsy showed minimal invasion of the MIS, but she was now happy to do so as she felt it was necessary and declared by the disease,' Patel said after the meeting. She was able to undergo an excision with clear margins, and a complex layered closure with a partial skin graft was performed, which she tolerated well. A Patient With SCC In Situ (SCCis) Another patient recently referred to Patel for discussion of Mohs surgery was an 89-year-old man who had multiple rough, scaly patches on his bald scalp, a history of prostate cancer, hypertension managed with hydrochlorothiazide, and no family history of melanoma or keratinocyte carcinomas. Biopsies on two areas of the scalp vertex within 1 cm of each other and one on the neck revealed an SCC in situ on the scalp with an adjacent actinic keratosis (AK). In addition, a biopsy on the neck revealed 'AK with focal SCCis,' Patel said at the meeting. 'We'd agree this patient does not need Mohs. But [in this case] we posed a question that was [examined] in a recent study: Does SCC in situ need treatment at all?' Patel said, referring to a single-center cohort study published in 2024 in which 411 consecutive SCCis tumors with a clinically resolved biopsy site were managed with watchful waiting. Of the 411 tumors, 17 recurred locally (4% recurrence rate), and there were no instances of nodal metastases, distant metastases, or disease-specific death. The highest risk for local recurrence was conferred by a history of solid-organ transplantation (hazard ratio [HR], 9.979; 95% CI, 2.249-39.69), and additional risk factors predicting local recurrence were location of the tumor on the vermillion lip or ear (HR, 9.744; 95% CI, 1.420-69.28) and on the head and neck (HR, 6.687; 95% CI, 1.583-36.15). The size of the lesion was also predictive of recurrence, with biopsies showing tumor extension to the deep edge being associated with a sixfold increased risk (HR, 6.562; 95% CI, 1.367-39.04). 'In typical, run-of-the-mill smaller SCCis, the vast majority of these lesions after biopsy did not recur,' Patel said. Many experts have proposed the consideration of topical therapy as a first-line treatment for SCCis, but 'the question sometimes comes up of whether we can identify patients' at a higher risk for recurrence, he said. A study published this year of 5-fluorouracil (5-FU) 5% cream for SCCis found that shorter treatment duration (particularly under 2 weeks) and larger lesion size (> 2 cm) were associated with a higher risk for treatment failure. Beyond that, there was no [impact] of immunosuppression or anatomic location, including hair-bearing locations, on the risk of recurrence, Patel said. The patient decided to pursue 2 weeks of therapy with 5-FU to help mitigate potential side effects, Patel said after the meeting. 'He did well….and we decided to monitor after the shortened treatment course.' Is Intralesional Treatment Coming? In the future, intralesional treatment may make skin cancer therapy 'even easier' for older patients, Patel said at the meeting. In a case report published in 2024, a 98-year-old wheelchair-bound 80-pound woman with frailty — and a 3.5-cm rapidly growing crusted nodule on her left proximal-lateral arm was treated with intralesional 5-FU — weekly for 4 weeks — after a shave biopsy revealed an invasive, well-differentiated SCC. There was no sign of recurrence at 3 months, and the patient died 6 months later of primary cardiac arrest, Patel said, noting that this was a case 'of doing no harm and limiting the morbidity associated with this tumor rather than approaching it from an aggressive standpoint.' A phase 3 trial of intralesional cemiplimab in patients with early-stage cutaneous SCC, newly underway at GW and multiple other sites, will look at how well the immune checkpoint inhibitor works when injected into the lesion, compared with surgery. The goal is to provide cutting-edge immunotherapy while potentially avoiding systemic toxicity, thus making this a viable nonsurgical option for older patients or those with surgical fatigue, Patel said after the meeting. Patel disclosed that he had received consulting honoraria from Regeneron Pharmaceuticals, Sun Pharma, Almirall, and Palvella Therapeutics, as well as research support from Regeneron Pharmaceuticals. He had served on the speaker's bureau with Regeneron Pharmaceuticals, Sun Pharma, and Almirall, and was the cofounder of the Skin Cancer Outcomes Consortium. Lead image: Moment/Getty Images Image 1: GWU Department of Dermatology

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

Yahoo

timean hour ago

  • Yahoo

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS). A unique RNA splice variant of the human gene called alpha-Klotho has been licensed by the Company from the Autonomous University of Barcelona ("UAB") including patents, patent applications, research, knowhow and other intellectual properties for use in the development of advanced gene and gene-engineered cell therapies. The human alpha-Klotho gene is located in cells found throughout the human body. It is a five exon gene that produces two protein isoforms: a full-length protein found mainly in cells of the kidney called membrane-bound Klotho (or m-KL), which controls phosphate homeostasis, and a much smaller protein isoform called secreted alpha-Klotho (or s-KL). The s-KL RNA splice variant is found mainly in the brain and spinal cord neurons; the variant protein is neuroprotective by minimizing both oxidative stress and neuroinflammation. Animal studies supported by the Company over the past two years in mouse and non-human primate models of rapid aging, in models of human Alzheimer's disease, and in models of ALS have shown that over-expression and amplification of the tissue levels of s-KL using a gene therapy approach result in highly favorable therapeutic outcomes in every model tested. These results have been published in peer-reviewed scientific journals and now support the transition of KLTO-202 into the clinical development stage. The Company expects that it will take approximately eight months to complete process development and manufacturing of KLTO-202, and about four to six months to conduct meetings with FDA, complete all FDA-mandated animal safety studies, file an investigational new drug application (IND), train and prepare clinical sites where the Phase I/II studies can be conducted, and then begin the single-dose gene therapy studies in ALS patients by the third quarter of next year. The Company will work with contract research organizations (CROs) to facilitate all activities including manufacturing and clinical trials without the need to hire several dozen staff members, which would significantly increase our operating overhead. Dr. Joseph Sinkule, the Company's CEO and founder commented: "With our recent fundraising success, we're moving forward with manufacturing the s-KL transgene DNA for KLTO-202. We've identified a more efficient method of producing the AAV vector to deliver the s-KL gene directly to motor neurons—the cells most affected by ALS. Our goal is to increase local s-KL protein levels to protect these neurons from the damage that leads to voluntary and involuntary muscle paralysis and ultimately death." ALS typically progresses rapidly, with most patients losing mobility, respiratory function, and life within just 2–3 years of diagnosis. About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFOir@ Website: Forward-Looking Statements: This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. SOURCE Klotho Neurosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store